IRF1 and tuberculosis: Moreover, miR-23a-3p was shown to inhibit monocyte function and phagocytosis by targeting IRF1/SP1 followed by the TLR4/TNF-α/TGF-β1/IL-10 signaling pathway in patients with active tuberculosis (Chen et al.2020).